Frontiers in Oncology (Jun 2019)

Combining the DNA Repair Inhibitor Dbait With Radiotherapy for the Treatment of High Grade Glioma: Efficacy and Protein Biomarkers of Resistance in Preclinical Models

  • Julian Biau,
  • Julian Biau,
  • Julian Biau,
  • Julian Biau,
  • Julian Biau,
  • Julian Biau,
  • Emmanuel Chautard,
  • Emmanuel Chautard,
  • Nathalie Berthault,
  • Nathalie Berthault,
  • Nathalie Berthault,
  • Nathalie Berthault,
  • Leanne de Koning,
  • Leanne de Koning,
  • Frank Court,
  • Bruno Pereira,
  • Pierre Verrelle,
  • Pierre Verrelle,
  • Pierre Verrelle,
  • Pierre Verrelle,
  • Marie Dutreix,
  • Marie Dutreix,
  • Marie Dutreix,
  • Marie Dutreix

DOI
https://doi.org/10.3389/fonc.2019.00549
Journal volume & issue
Vol. 9

Abstract

Read online

High grade glioma relapses occur often within the irradiated volume mostly due to a high resistance to radiation therapy (RT). Dbait (which stands for DNA strand break bait) molecules mimic DSBs and trap DNA repair proteins, thereby inhibiting repair of DNA damage induced by RT. Here we evaluate the potential of Dbait to sensitize high grade glioma to RT. First, we demonstrated the radiosensitizer properties of Dbait in 6/9 tested cell lines. Then, we performed animal studies using six cell derived xenograft and five patient derived xenograft models, to show the clinical potential and applicability of combined Dbait+RT treatment for human high grade glioma. Using a RPPA approach, we showed that Phospho-H2AX/H2AX and Phospho-NBS1/NBS1 were predictive of Dbait efficacy in xenograft models. Our results provide the preclinical proof of concept that combining RT with Dbait inhibition of DNA repair could be of benefit to patients with high grade glioma.

Keywords